Profund Advisors LLC Intercept Pharmaceuticals, Inc. Transaction History

Profund Advisors LLC

$2.65 Billion
Q2 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$9.99 - $18.71 $225,324 - $422,004	-22,555 Reduced 30.61%	51,133 $948,000
Q2 2023 Aug 10, 2023	BUY	$9.17 - $19.29 $237,136 - $498,839	25,860 Added 54.07%	73,688 $814,000
Q1 2023 May 11, 2023	BUY	$12.53 - $21.71 $599,284 - $1.04 Million	47,828 New	47,828 $642,000
Q3 2020 Nov 13, 2020	SELL	$39.09 - $53.44 $236,533 - $323,365	-6,051 Closed	0 $0
Q2 2020 Aug 03, 2020	BUY	$46.7 - $92.04 $40,675 - $80,166	871 Added 16.81%	6,051 $290,000
Q1 2020 May 15, 2020	SELL	$48.35 - $118.68 $104,484 - $256,467	-2,161 Reduced 29.44%	5,180 $326,000
Q4 2019 Feb 18, 2020	BUY	$57.36 - $124.1 $53,459 - $115,661	932 Added 14.54%	7,341 $910,000
Q3 2019 Nov 12, 2019	BUY	$58.69 - $80.46 $586 - $804	10 Added 0.16%	6,409 $425,000
Q2 2019 Aug 13, 2019	BUY	$77.77 - $120.68 $22,164 - $34,393	285 Added 4.66%	6,399 $509,000
Q1 2019 May 15, 2019	BUY	$91.83 - $120.68 $6,152 - $8,085	67 Added 1.11%	6,114 $684,000
Q4 2018 Feb 14, 2019	SELL	$85.79 - $126.46 $123,623 - $182,228	-1,441 Reduced 19.24%	6,047 $609,000
Q3 2018 Nov 13, 2018	BUY	$88.49 - $127.55 $87,516 - $126,146	989 Added 15.22%	7,488 $946,000
Q2 2018 Aug 13, 2018	BUY	$60.0 - $85.67 $33,540 - $47,889	559 Added 9.41%	6,499 $545,000
Q1 2018 May 14, 2018	SELL	$52.72 - $67.25 $33,160 - $42,300	-629 Reduced 9.58%	5,940 $365,000
Q4 2017 Feb 14, 2018	SELL	$58.2 - $72.76 $47,316 - $59,153	-813 Reduced 11.01%	6,569 $384,000
Q3 2017 Nov 13, 2017	BUY	$57.01 - $118.75 $33,578 - $69,943	589 Added 8.67%	7,382 $428,000
Q2 2017 Aug 11, 2017	BUY	N/A	6,793	6,793 $822,000

Others Institutions Holding ICPT

# of Institutions

Shares Held

1.04M

Call Options Held

30K

Put Options Held

5.9K

View Full List

About INTERCEPT PHARMACEUTICALS, INC.

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

More about ICPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Account